Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34314927

about

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia Genetic abnormalities associated with acute lymphoblastic leukemia Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Translating cancer genomes and transcriptomes for precision oncology Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase Drugging the unfolded protein response in acute leukemias Diagnosis and subclassification of acute lymphoblastic leukemia Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine Clinical tumor sequencing: opportunities and challenges for precision cancer medicine Recent advances and novel treatment paradigms in acute lymphocytic leukemia Childhood acute lymphoblastic leukemia: Integrating genomics into therapy CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia How I treat acute lymphoblastic leukemia in older adolescents and young adults Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration TRKing down an old oncogene in a new era of targeted therapy LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.Biology of childhood acute lymphoblastic leukemia.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model Novel agents for the treatment of childhood acute leukemia.Generation of human acute lymphoblastic leukemia xenografts for use in oncology drug discovery.mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.Structure of the ABL2/ARG kinase in complex with dasatinib Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature.YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia

P2860

bb1ebf0a70932924dcf1fd88ad4b2b1508148718

P248

Q26749177-F9FAC0C5-4FCC-4168-9516-4D2F374C2620 Q26753823-A3302E69-5BC6-45D7-AED9-4562A28E35E1 Q26768158-9A256884-F452-4484-9A7B-5045E8D53423 Q26777081-1E6421DC-14F7-4E02-AC56-0807DF576272 Q26781328-6348970A-5150-4067-A12F-02592BE8E3B7 Q26784116-36ACE894-725F-47BA-8E1F-F2F8E6D11224 Q26801114-A9FE51F8-CCB2-4D17-BB1F-C37E0377F0B5 Q26824387-F2BC0D4D-6954-470F-A3AD-B65DDB8281FF Q26864460-20C924DE-64A7-494A-8FD5-0A61BDB6E0C1 Q27027942-B31900FA-491C-4B43-AA98-E71DA1CD7914 Q28078076-20D7B984-FDE3-4424-9810-44CB450D57F6 Q28080463-6A5135B8-37CF-4F93-B701-28A08862AC06 Q28084879-69266F7B-551F-454B-8CA5-F73E6C690C61 Q28087589-38144C12-A9CE-4550-9E79-22C5D1BC37F3 Q28087637-12E4AFF8-E625-4311-89D2-B835242AE972 Q28254287-5B168E55-5414-4F8D-82C8-101423FFDBC6 Q28274115-DD001BA0-7C8B-4D89-BCF3-10B1699F8328 Q28276513-77528699-0BDC-4B89-8820-5A7EA9DC8152 Q30243925-415166F5-9D25-4972-B0EE-493D83F3F723 Q33422654-BBB9135B-38BF-45CA-8E2F-EE5E09B228C9 Q33423823-676BE685-09C5-4232-A23C-DF9BBEF12469 Q33578333-3C21317C-1F73-47CE-B280-7064CB32EBEC Q33698398-3F674517-548E-48D6-886D-B0B2B84F5DE0 Q33746736-00D0E6CB-BF27-4C7C-A75D-A7B600D63BF9 Q33770150-BF4707EC-4CAA-41AF-B4DC-49FDFB278088 Q34482019-A163DBF9-7C32-4930-9F2D-EC9306E9F5DF Q34605953-C320079C-797D-4AA8-9194-6FB296066FD1 Q35004970-FA64D8D9-F482-4641-9A21-64F0944E837D Q35079398-94253786-D338-48DF-A03B-E67178E3292D Q35126258-B6B071B9-033C-44B0-9339-2107FF4617FC Q35129383-6FD0C66E-B68C-4423-B8C5-A679FC728D60 Q35146312-44F6B7BB-A774-4109-B212-8F7D80A8EA0C Q35176311-CC2654FD-7ECA-4714-AA23-F51A79400A1C Q35192790-4B5C3FC9-6F7D-40E9-ADA1-C524513CE5DA Q35205279-4A00E88F-50D5-4AF7-9654-13B5F5693B3C Q35273390-02143783-F992-4E63-9264-7187426E2254 Q35299103-861A78D5-9455-48AF-9344-0A5219457F99 Q35531034-B238F5D7-1813-497D-9584-87EB8DD4DFF3 Q35534316-DFB7F70D-4E7D-4C9E-AA78-A566D8271F3A Q35637452-A498143E-DEF8-4466-A5F2-C207EA530B1B

P2860

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34314927

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@ast

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@en

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@nl

type

label

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@ast

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@en

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@nl

prefLabel

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@ast

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@en

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@nl

P1433

Q34314927-18FDA593-9C18-4C45-AD4E-62DB4FA18F10

P1476

Q34314927-A941A977-37A0-4E6F-904D-E5DA60B6462E

P2093

Q34314927-011607DE-0610-4EB3-8FDE-5849CF476EC0

Q34314927-04ACE2C2-9BF4-4796-AAD9-BE8F7B52464B

Q34314927-065B0D31-7938-478E-A3EE-B1BE29CB89A3

Q34314927-067C83C1-F512-4E07-9560-0B53B265DBEB

Q34314927-0A8E6116-CAD1-4E70-A74A-A23E4D324CBF

Q34314927-0D031701-133E-4F7D-A105-EFAD74C77513

Q34314927-0E0F2912-3EBA-4E8D-BD3F-4F3C4C4F3336

Q34314927-0F5EDB14-FC6A-4748-84BD-E3EBAABCA596

Q34314927-0F9EC751-D87A-4A7E-AEA5-F1FD3EA1DF18

Q34314927-129C6A47-5433-4808-A91F-9C90D44B36C2

P2860

Q34314927-08020503-E6E8-40C6-91B7-D2309289E7C2

Q34314927-11BCA527-2ED2-4EA8-B83C-C4CF118B0811

Q34314927-1449B6F9-FA54-4375-9ADD-1615FB6FFA4E

Q34314927-160D6F59-795C-436E-9B8B-17BFAE89849E

Q34314927-312A643D-1014-4261-9AD4-CA2B911FF243

Q34314927-338BD293-1499-4C0C-A8B2-FBF21D13CCBA

Q34314927-38758E16-EC41-4955-A051-756565B24EC2

Q34314927-402CA3AB-E28C-41C5-A5A2-AED217C7BC9B

Q34314927-61B0E40B-3BEC-45E5-B42A-ED6F2F06C346

Q34314927-61B986CD-789B-4D9D-B610-2AC18CC235BF

P304

Q34314927-81DE1DA3-94E0-4059-A5DB-B5C22A8BEF6B

P31

Q34314927-753BC8CE-026B-4E77-BB34-BC00FB8BB53A

P356

Q34314927-94471A9A-A5D7-4BCB-AF72-017187708391

P407

Q34314927-0FA976EE-74D1-436D-8060-591055C89DCE

P433

Q34314927-7D16715D-1417-4E5F-88C1-2B93882F19CA

P478

Q34314927-BF824EF7-98D8-4A83-BA1C-AD69D485B165

P50

Q34314927-1AC4A6D7-AE31-4F83-AF7D-BB84592D58E1

Q34314927-1D7D4622-6F85-4AAE-93E3-E929E998338A

Q34314927-1E55FB45-EED2-4321-B4F4-E5F84546BB69

Q34314927-3049CA0F-1556-49D1-A05B-882E62F92AD5

Q34314927-36D95DFB-C59E-4B38-9439-D58EC8B3A1D4

Q34314927-4061774B-7200-458B-9CB9-E53FB6D46BF2

Q34314927-450BE63B-955E-44CB-B551-0D802E917310

Q34314927-4E3703DB-F614-486B-A7C3-8F6D5D8B0FA2

Q34314927-5AA7E01F-0B4E-4918-BDFC-6803587A2EB9

Q34314927-80D0A9CC-895E-47F4-930E-D34D244CA8AF

P577

Q34314927-3B5BD2CB-75CA-4703-9400-B6C7C4DC094B

P698

Q34314927-CAC4EC13-1319-48B8-A436-7070E0CB6815

P921

Q34314927-FE62353C-85D1-4042-8923-6FB2361E25B9

P932

Q34314927-54B570C6-0F6F-4A67-AF8C-2356BA49156B

P356

P1433

The New England Journal of Medicine

P1476

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

@en

P2093

Amy Smith

http://www.w3.org/2001/XMLSchema#string

Andrew J Carroll

http://www.w3.org/2001/XMLSchema#string

Bhavin Vadodaria

http://www.w3.org/2001/XMLSchema#string

Charles Lu

http://www.w3.org/2001/XMLSchema#string

Cheng Cheng

http://www.w3.org/2001/XMLSchema#string

Cheryl L Willman

http://www.w3.org/2001/XMLSchema#string

Daniela S Gerhard

http://www.w3.org/2001/XMLSchema#string

Debbie Payne-Turner

http://www.w3.org/2001/XMLSchema#string

Deqing Pei

http://www.w3.org/2001/XMLSchema#string

Donald Yergeau

http://www.w3.org/2001/XMLSchema#string

P2860

Acute lymphoblastic leukaemia

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma

Role of ABL family kinases in cancer: from leukaemia to solid tumours

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

Evaluation of survival data and two new rank order statistics arising in its consideration.

Adolescents and young adults with acute lymphoblastic leukemia.

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

P304

1005-1015

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1403088

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Charles G. Mullighan

Sarah K. Tasian

Deborah L. White

Kelly McCastlain

Clara D. Bloomfield

Richard C Harvey

Malcolm A Smith

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25207766

http://www.w3.org/2001/XMLSchema#string

P921

P932

4191900

http://www.w3.org/2001/XMLSchema#string